Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent in the local language prior to any study-mandated procedure.~* Women must have~  * a negative serum pregnancy test at screening and~ * a negative urine pregnancy test pre-dose on Day-1 of each treatment period.~* Women of childbearing potential must consistently and correctly use (from screening, during the entire study, and for at least 28 days after last study drug intake) a reliable method of contraception with a failure rate of \< 1% per year, be sexually inactive, or have a vasectomized partner.~Women not of childbearing potential are defined as post-menopausal (i.e., spontaneous amenorrhea for at least 1 year without an alternative medical cause) or surgically or naturally sterile.~* No clinically significant findings on the physical examination at screening.~* Body mass index (BMI) of 18.0 to 28.0 kg/m\^2 (inclusive) at screening.~* Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate (PR) 45-90 bpm (inclusive), measured on the dominant arm (dominant arm = writing arm) after 5 minutes in the supine position at screening.~* 12-lead electrocardiogram (ECG) without clinically relevant abnormalities, measured after 5 minutes in the supine position at screening.~* Hematology, clinical chemistry, and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening.~* Negative results from urine drug screen and breath alcohol test at screening and on admission to the unit (Day-1) in Period 1 and Period 2.~* Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.~Exclusion Criteria:~* Pregnant or lactating women.~* Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s).~* History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy and herniotomy allowed, cholecystectomy not allowed).~* Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.~* History or clinical evidence of allergic rhinitis or asthma.~* Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture).~* Previous exposure to the study medication.~* Treatment with another investigational drug within 3 months prior to screening or participation in more than four investigational drug studies within 1 year prior to screening.~* History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.~* Excessive caffeine consumption, defined as 800 mg per day at screening.~* Alcohol consumption of \> 21 units/week or \> 3 units/day.~* Smoking within 3 months prior to screening.~* Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to first study drug administration.~* Loss of 250 mL or more of blood within 3 months prior to screening.~* Positive results from the hepatitis serology (Hepatitis B surface antigen and anti-hepatitis C virus), except for vaccinated subjects or subjects with past but resolved hepatitis (defined as positive finding for antibodies but negative findings for antigens), at screening.~* Positive results from the human immunodeficiency virus serology at screening.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.~* Legal incapacity or limited legal capacity at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ACT-129968 tablet/capsules (Type: EXPERIMENTAL): Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
- ACT-129968 capsules/tablet (Type: EXPERIMENTAL): Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).